Date de publication
Géographie
Langue de la ressource
Texte disponible en version intégrale
Open Access / OK to Reproduce
Évalué par des pairs
L’objectif
To ensure optimal management of opioid use disorder (OUD), the updated 2024 CRISM National Guideline incorporates recent research, clinical insights, and input from individuals with lived experience, aiming to provide evidence-based high-standard care practices. This guideline is designed for decision-making in the general care of patients with OUD.
Constatations/points à retenir
The recommendations suggest that buprenorphine and methadone should both be considered as first-line treatment options and slow-release oral morphine should be available and offered as a second-line option. The document includes recommended evidence-based approach for withdrawal management, complementary evidence-based interventions: psychosocial and harm reduction interventions.
A synopsis of the Guideline was published in the Canadian Medical Association Journal (November 12, 2024) or download the PDF.
